Health Wire Syria: Press Releases

$AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1$

January 7, 2026

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

GlobeNewswire

$AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia$

January 7, 2026

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

GlobeNewswire

GENFIT Announces 2026 Financial Calendar

January 7, 2026

Scottish Rite for Children Receives $2.3M NIH Grant to Advance Bone Regeneration Research in Children With Perthes Disease

GlobeNewswire

January 7, 2026

USOSM Continues Growth Momentum

GlobeNewswire

January 7, 2026

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

GlobeNewswire

January 7, 2026

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

GlobeNewswire

Health Wire Syria: Press Releases

November 2025

December 2025

January 2026

Press releases published on January 7, 2026

HyperCharge Health issues new statement calling for increased attention on Minnesota's Lyme Disease Crisis

Koelis Announces Designated CPT I Codes for Fusion Biopsy and Transperineal Biopsy in Prostate Cancer Diagnosis

Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody

Pinnacle Treatment Centers Appoints Brian Lantier as Chief Executive Officer

Pioneering Scientist Behind Revolutionary Weight-Loss Drugs and Leading Mathematician Honored with 2026 King Faisal Prize

Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease

300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition

AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

GENFIT Announces 2026 Financial Calendar

GENFIT annonce son calendrier financier pour 2026

Comprehensive Healthcare Welcomes Community Behavioral Health Veteran as Chief Medical Officer

Neocis Surpasses 100,000 Robotic Osteotomies with the Yomi Platform

National Institutes of Health Awards $1.54M Grant To Scottish Rite for Children for Rare Diseases Research

ENT & Allergy Associates Welcomes Otolaryngologist Christopher V. Lisi, MD to its West Nyack, NY Office

Cullgen Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Scottish Rite for Children Receives $2.3M NIH Grant to Advance Bone Regeneration Research in Children With Perthes Disease

USOSM Continues Growth Momentum

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences